166 related articles for article (PubMed ID: 32923849)
1. Genomic Characterization of
Mondaca S; Razavi P; Xu C; Offin M; Myers M; Scaltriti M; Hechtman JF; Bradley M; O'Reilly EM; Berger MF; Solit DB; Li BT; Abou-Alfa GK
JCO Precis Oncol; 2019; 3():. PubMed ID: 32923849
[TBL] [Abstract][Full Text] [Related]
2. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
3. Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.
Papadopoulou K; Murray S; Manousou K; Tikas I; Dervenis C; Sgouros J; Rontogianni D; Lakis S; Bobos M; Poulios C; Pervana S; Lazaridis G; Fountzilas G; Kotoula V
Am J Cancer Res; 2018; 8(1):2-15. PubMed ID: 29416916
[TBL] [Abstract][Full Text] [Related]
4. KRAS Allelic Variants in Biliary Tract Cancers.
Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H; Xu Y; Gao W; Li M; He J; Deng X; Xing W
Front Oncol; 2022; 12():930611. PubMed ID: 36072793
[TBL] [Abstract][Full Text] [Related]
6. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
7. Rates of
Gottesdiener LS; O'Connor S; Busam KJ; Won H; Solit DB; Hyman DM; Shoushtari AN
Clin Cancer Res; 2018 Dec; 24(23):5815-5819. PubMed ID: 30093446
[TBL] [Abstract][Full Text] [Related]
8. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
9. Biliary tract cancer prognostic and predictive genomics.
Mondaca S; Nervi B; Pinto M; Abou-Alfa GK
Chin Clin Oncol; 2019 Aug; 8(4):42. PubMed ID: 31431036
[TBL] [Abstract][Full Text] [Related]
10. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients.
Yang P; Javle M; Pang F; Zhao W; Abdel-Wahab R; Chen X; Meric-Bernstam F; Chen H; Borad MJ; Liu Y; Zou C; Mu S; Xing Y; Wang K; Peng C; Che X
Hepatobiliary Surg Nutr; 2019 Dec; 8(6):604-614. PubMed ID: 31929987
[TBL] [Abstract][Full Text] [Related]
11. Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing.
Yoo KH; Kim NK; Kwon WI; Lee C; Kim SY; Jang J; Ahn J; Kang M; Jang H; Kim ST; Ahn S; Jang KT; Park YS; Park WY; Lee J; Heo JS; Park JO
Transl Oncol; 2016 Jun; 9(3):173-8. PubMed ID: 27267833
[TBL] [Abstract][Full Text] [Related]
12. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
[TBL] [Abstract][Full Text] [Related]
14. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract.
Roos E; Soer EC; Klompmaker S; Meijer LL; Besselink MG; Giovannetti E; Heger M; Kazemier G; Klümpen HJ; Takkenberg RB; Wilmink H; Würdinger T; Dijk F; van Gulik TM; Verheij J; van de Vijver MJ
Crit Rev Oncol Hematol; 2019 Aug; 140():8-16. PubMed ID: 31158800
[TBL] [Abstract][Full Text] [Related]
15. Gallbladder cancer harboring
Inagaki C; Maeda D; Kimura A; Otsuru T; Iwagami Y; Nishida N; Sakai D; Shitotsuki R; Yachida S; Doki Y; Satoh T
World J Gastrointest Oncol; 2019 Sep; 11(9):761-767. PubMed ID: 31558980
[TBL] [Abstract][Full Text] [Related]
16. Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice.
Lin J; Dong K; Bai Y; Zhao S; Dong Y; Shi J; Shi W; Long J; Yang X; Wang D; Yang X; Zhao L; Hu K; Pan J; Sang X; Wang K; Zhao H
Ann Transl Med; 2019 Sep; 7(18):467. PubMed ID: 31700903
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of ado-trastuzumab emtansine in patients with ERBB2-aberrant non-small cell lung cancer: a systematic review.
Huang X; Jin R; Lou L; Zhao J; Xia L; Zhao J; Li W; Xu Z; Xia Y
Transl Cancer Res; 2020 Aug; 9(8):4507-4516. PubMed ID: 35117816
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in Japanese extrahepatic biliary tract cancer.
Noguchi R; Yamaguchi K; Ikenoue T; Terakado Y; Ohta Y; Yamashita N; Kainuma O; Yokoi S; Maru Y; Nagase H; Furukawa Y
Oncol Lett; 2017 Jul; 14(1):877-884. PubMed ID: 28693246
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With
Cannon TL; Rothe M; Mangat PK; Garrett-Mayer E; Chiu VK; Hwang J; Vijayvergia N; Alese OB; Dib EG; Duvivier HL; Klute KA; Sahai V; Ahn ER; Bedano P; Behl D; Sinclair S; Thota R; Urba WJ; Yang ES; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
J Clin Oncol; 2024 May; ():JCO2302078. PubMed ID: 38748939
[TBL] [Abstract][Full Text] [Related]
20. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
